Issue Date: April 23, 2012
Piramal Snags Imaging Agents From Bayer
Piramal Healthcare will acquire Bayer’s molecular-imaging R&D portfolio for an undisclosed sum. The portfolio includes rights to florbetaben, a diagnostic that detects amyloid-β plaque deposits in the brain. The plaque is considered an indicator of Alzheimer’s disease. Piramal says the portfolio has a potential value of $1.5 billion. The deal marks Piramal’s second acquisition of a late-stage asset; last year, the Indian firm bought a cartilage repair product that has . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society